...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Cytokine >Soluble CD163, a unique biomarker to evaluate the disease activity, exhibits macrophage activation in systemic juvenile idiopathic arthritis
【24h】

Soluble CD163, a unique biomarker to evaluate the disease activity, exhibits macrophage activation in systemic juvenile idiopathic arthritis

机译：可溶性CD163是一种评价疾病活动的独特生物标志物，在全身性幼年特发性关节炎中表现出巨噬细胞活化

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

This study aims to investigate the clinical significance of serum soluble CD163 (sCD163) levels as a predictor of the disease activity of systemic juvenile idiopathic arthritis (s-JIA). In this study, we examined 63 patients with s-JIA, four with Epstein-Barr virus-induced hemophagocytic lymphohistiocytosis (EBV-HLH), and seven with Kawasaki disease (KD), along with 14 healthy controls. We quantified serum cytokine levels (sCD163, neopterin, IL-18, IL-6) by enzyme-linked immunosorbent assay and compared the results with the clinical features of s-JIA. Serum sCD163 levels were significantly elevated in patients with s-JIA associated macrophage activation syndrome (MAS) and EBV-HLH compared to those in patients with acute-phase s-JIA and KD. In addition, serum sCD163 levels profoundly increased with the progress of MAS and correlated positively with the disease activity of s-JIA, even in patients receiving tocilizumab. Furthermore, serum sCD163 levels significantly decreased in the inactive phase compared to those in the active phase and normalized in remission. The correlation between macrophage activation and serum sCD163 levels might be a unique indicator of the disease activity and a potential diagnostic laboratory criterion for clinical remission in patients with s-JIA, including those receiving tocilizumab.
机译：本研究旨在探讨血清可溶性CD163（SCD163）水平作为全身性幼年特发性关节炎（S-JIA）疾病活性的预测的临床意义。在这项研究中，我们研究了63例S-JIA患者，其中四个患有Epstein-Barr病毒诱导的血糖淋巴管菌症（EBV-HLH），七种与Kawasaki疾病（KD）以及14例健康对照。通过酶联免疫吸附试验量化血清细胞因子水平（SCD163，Neopterin，IL-18，IL-6），并将结果与​​S-JIA的临床特征进行了比较。 S-JIA相关巨噬细胞激活综合征（MAS）和EBV-HLH的患者血清SCD163水平显着升高，与急性期S-jia和Kd患者的患者相比。此外，随着MAS的进展，血清SCD163水平正在增加，并随着S-JIA的疾病活性而相关，即使在接受托运珠三角的患者中也是如此。此外，与活性相的相比，血清SCD163水平在无活性阶段显着降低，并在缓解中归一化。巨噬细胞活化和血清SCD163水平之间的相关性可能是疾病活动的独特指标和S-jia患者临床缓解的潜在诊断实验室标准，包括接受TOCOLIZUMAB的患者。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号